Top

Osteoporosis International

Published in:

01-06-2021 | Bisphosphonate | Original Article

The efficacy and safety of bisphosphonate analogs for treatment of osteoporosis after spinal cord injury: a systematic review and meta-analysis of randomized controlled trials

Authors: Y. Wu, F. Wang, Z. Zhang

Published in: Osteoporosis International | Issue 6/2021

Abstract

Summary

Bisphosphonates can inhibit osteoclast-mediated bone resorption, prevent bone loss, and reduce the risk of osteoporotic fractures. Our meta-analysis of studies shows that early bisphosphonate administration after SCI was safe and beneficial to the BMD of the total hip and lumbar spine at 12 months.

Introduction

Rapid bone loss in the early stages of spinal cord injury (SCI) leads to an increased risk of osteoporotic fracture. A meta-analysis was conducted to assess the efficacy and safety of bisphosphonates for the treatment of osteoporosis after SCI.

Methods

A literature search of the PubMed, EMBASE, Cochrane Library, and Web of Science databases identified nine randomized controlled trials with 206 individuals. This meta-analysis was performed using a random-effects model. The primary outcome was the percent change in bone mineral density (BMD) of the total hip, distal femur, and lumbar spine from baseline to 12 months. Bone turnover markers were secondary outcomes. The incidences of adverse events were assessed in order to evaluate safety.

Results

There were significant differences in BMD of the total hip and lumbar spine or serum C-terminal telopeptide between the bisphosphonate and control groups but no difference in adverse events. The percent change in BMD of the distal femur and serum type 1 procollagen N-terminal peptide from baseline to 12 months was not superior in the treatment groups. Osteoclast-mediated bone resorption was inhibited by bisphosphonate administration. Subgroup analyses of participants treated with zoledronate at different sites revealed a beneficial effect on BMD of the total hip and lumbar spine but not the distal femur.

Conclusion

Early bisphosphonate administration after SCI was safe and beneficial to the BMD of the total hip and lumbar spine at 12 months.

Xie J, Deng X, Feng Y, Cao N, Zhang X, Fang F, Zhang S, Feng Y (2018) Early intradural microsurgery improves neurological recovery of acute spinal cord injury: a study of 87 cases. J Neurorestoratol 6(1):152–157. https://doi.org/10.26599/jnr.2018.9040014CrossRef

Kang Y, Ding H, Zhou H, Wei Z, Liu L, Pan D, Feng S (2018) Epidemiology of worldwide spinal cord injury: a literature review. J Neurorestoratol 6(1):1–9. https://doi.org/10.2147/jn.S143236CrossRef

Eser P, Frotzler A, Zehnder Y, Wick L, Knecht H, Denoth J, Schiessl H (2004) Relationship between the duration of paralysis and bone structure: a pQCT study of spinal cord injured individuals. Bone 34(5):869–880. https://doi.org/10.1016/j.bone.2004.01.001CrossRefPubMed

Garland DE (1992) Osteoporosis after spinal cord injury. J Orthop Res 10:371–378CrossRefPubMed

Minoshima M, Kikuta J, Omori Y, Seno S, Suehara R, Maeda H, Matsuda H, Ishii M, Kikuchi K (2019) In vivo multicolor imaging with fluorescent probes revealed the dynamics and function of osteoclast proton pumps. ACS Cent Sci 5(6):1059–1066. https://doi.org/10.1021/acscentsci.9b00220CrossRefPubMedPubMedCentral

Jiang SD, Dai LY, Jiang LS (2006) Osteoporosis after spinal cord injury. Osteoporos Int 17(2):180–192. https://doi.org/10.1007/s00198-005-2028-8CrossRefPubMed

Soleyman-Jahi S, Yousefian A, Maheronnaghsh R, Shokraneh F, Zadegan SA, Soltani A, Hosseini SM, Vaccaro AR, Rahimi-Movaghar V (2018) Evidence-based prevention and treatment of osteoporosis after spinal cord injury: a systematic review. Eur Spine J 27(8):1798–1814. https://doi.org/10.1007/s00586-017-5114-7CrossRefPubMed

Fleisch H (1993) New bisphosphonates in osteoporosis. Osteoporos Int 3:S15–S22CrossRefPubMed

Brodowicz T, O’Byrne K, Manegold C (2012) Bone matters in lung cancer. Ann Oncol 23(9):2215–2222. https://doi.org/10.1093/annonc/mds009CrossRefPubMedPubMedCentral

10.

Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ (2017) Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases. J Clin Oncol 35(35):3949–3955. https://doi.org/10.1200/JCO.2017.73.7437CrossRefPubMedPubMedCentral

11.

Moher D, Liberati A, Tetzlaff J (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535CrossRefPubMedPubMedCentral

12.

Jokstad A (2017) Cochrane Collaboration Systematic Reviews may be based on trials not approved by a research ethics committee. Clin Exp Dent Res 3(5):179–182CrossRefPubMedPubMedCentral

13.

Chang KV, Chen SY, Chen WS, Tu YK, Chien KL (2012) Comparative effectiveness of focused shock wave therapy of different intensity levels and radial shock wave therapy for treating plantar fasciitis: a systematic review and network meta-analysis. Arch Phys Med Rehabil 93:1259–1268. https://doi.org/10.1016/j.apmr.2012.02.023CrossRefPubMed

14.

Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13. https://doi.org/10.1186/1471-2288-5-13CrossRefPubMedPubMedCentral

15.

Li T, Ma J, Zhao T, Gao F, Sun W (2019) Application and efficacy of extracorporeal shockwave treatment for knee osteoarthritis: a systematic review and meta-analysis. Exp Ther Med 18(4):2843–2850. https://doi.org/10.3892/etm.2019.7897CrossRefPubMedPubMedCentral

16.

Thorlund K, Imberger G, Johnston BC, Walsh M, Awad T, Thabane L, Gluud C, Devereaux PJ, Wetterslev J (2012) Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS One 7(7):e39471CrossRefPubMedPubMedCentral

17.

Firth J, Teasdale SB, Allott K, Siskind D, Marx W, Cotter J, Veronese N, Schuch F, Smith L, Solmi M, Carvalho AF, Vancampfort D, Berk M, Stubbs B, Sarris J (2019) The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry 18(3):308–324. https://doi.org/10.1002/wps.20672CrossRefPubMedPubMedCentral

18.

Bradburn MJ, Deeks JJ, Berlin JA (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26(1):53–77CrossRefPubMed

19.

Park HR, Kim JH, Lee D, Jo HG (2019) Cangfu daotan decoction for polycystic ovary syndrome: a protocol of systematic review and meta-analysis. Medicine (Baltimore) 98(39):e17321. https://doi.org/10.1097/MD.0000000000017321CrossRef

20.

Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, Tonelli M, Covic A, Strippoli GF (2013) Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 10(4):e1001436. https://doi.org/10.1371/journal.pmed.1001436CrossRefPubMedPubMedCentral

21.

Bauman WA, Wecht JM, Kirshblum S, Spungen AM, Morrison N, Cirnigliaro C, Schwartz E (2005) Effect of pamidronate administration on bone in patients with acute spinal cord injury. J Rehabil Res Dev 42(3):305–313. https://doi.org/10.1682/JRRD.2004.05.0062CrossRefPubMed

22.

Bubbear JS, Gall A, Middleton FR, Ferguson-Pell M, Swaminathan R, Keen RW (2011) Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury. Osteoporos Int 22(1):271–279. https://doi.org/10.1007/s00198-010-1221-6CrossRefPubMed

23.

Gilchrist NL, Frampton CM, Acland RH, Nicholls MG, March RL, Maguire P, Heard A, Reilly P, Marshall K (2007) Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 92(4):1385–1390. https://doi.org/10.1210/jc.2006-2013CrossRefPubMed

24.

Goenka S, Sethi S, Pandey N, Joshi M, Jindal R (2018) Effect of early treatment with zoledronic acid on prevention of bone loss in patients with acute spinal cord injury: a randomized controlled trial. Spinal Cord 56(12):1207–1211. https://doi.org/10.1038/s41393-018-0195-7CrossRefPubMed

25.

Moran De Brito CM, Battistella LR, Saito ET, Sakamoto H (2005) Effect of alendronate on bone mineral density in spinal cord injury patients: a pilot study. Spinal Cord 43(6):341–348. https://doi.org/10.1038/sj.sc.3101725CrossRefPubMed

26.

Oleson CV, Marino RJ, Formal CS, Modlesky CM, Leiby BE (2020) The effect of zoledronic acid on attenuation of bone loss at the hip and knee following acute traumatic spinal cord injury: a randomized-controlled study. Spinal Cord 58:921–929. https://doi.org/10.1038/s41393-020-0431-9CrossRefPubMed

27.

Schnitzer TJ, Kim K, Marks J, Yeasted R, Simonian N, Chen D (2016) Zoledronic acid treatment after acute spinal cord injury: results of a randomized, placebo-controlled pilot trial. Pm r 8(9):833–843. https://doi.org/10.1016/j.pmrj.2016.01.012CrossRefPubMed

28.

Shapiro J, Smith B, Beck T, Ballard P, Dapthary M, BrintzenhofeSzoc K, Caminis J (2007) Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury. Calcif Tissue Int 80(5):316–322. https://doi.org/10.1007/s00223-007-9012-6CrossRefPubMed

29.

Varghese SM, Chandy BR, Thomas R, Tharion G (2016) Effect of zoledronic acid on osteoporosis after chronic spinal cord injury: a randomized controlled trial. Crit Rev Phys Rehabil Med 28(1-2):85–93. https://doi.org/10.1615/CritRevPhysRehabilMed.2016018768CrossRef

30.

Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 7041(312):1254–1259. https://doi.org/10.1136/bmj.312.7041.1254CrossRef

31.

Garland DE, Adkins RH, Kushwaha V, Stewart C (2004) Risk factors for osteoporosis at the knee in the spinal cord injury population. J Spinal Cord Med 27(3):202–206. https://doi.org/10.1080/10790268.2004.11753748CrossRefPubMed

32.

Bauman WA, Cirnigliaro CM, La Fountaine MF, Martinez LA, Kirshblum SC, Spungen AM (2015) Zoledronic acid administration failed to prevent bone loss at the knee in persons with acute spinal cord injury: an observational cohort study. J Bone Miner Metab 33(4):410–421. https://doi.org/10.1007/s00774-014-0602-xCrossRefPubMed

33.

Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi JD, Shea B, Tugwell P, Guyatt G (2002) Metaanalyses of therapies for postmenopausal osteoporosis. II. Metaanalysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508–516CrossRefPubMed

34.

Nance PW, Schryvers O, Leslie W, Ludwig S, Krahn J, Uebelhart D (1999) Intravenous pamidronate attenuates bone density loss after acute spinal cord injury. Arch Phys Med Rehabil 3(80):243–251CrossRef

35.

Zehnder Y, Risi S, Michel D, Knecht H, Perrelet R, Kraenzlin M, Zäch GA, Lippuner K (2004) Prevention of bone loss in paraplegics over 2 years with alendronate. J Bone Miner Res 19(7):1067–1074. https://doi.org/10.1359/JBMR.040313CrossRefPubMed

Title: The efficacy and safety of bisphosphonate analogs for treatment of osteoporosis after spinal cord injury: a systematic review and meta-analysis of randomized controlled trials
Authors: Y. Wu
F. Wang
Z. Zhang
Publication date: 01-06-2021
Publisher: Springer London
Keywords: Bisphosphonate
Osteoporosis
Osteoporosis
Published in: Osteoporosis International / Issue 6/2021
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-020-05807-0

At a glance: The STEP trials

Springer Medicine

The efficacy and safety of bisphosphonate analogs for treatment of osteoporosis after spinal cord injury: a systematic review and meta-analysis of randomized controlled trials

Abstract

Summary

Introduction

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2021

Calcification of lower extremity arteries is related to the presence of osteoporosis in postmenopausal women with type 2 diabetes mellitus: a cross-sectional observational study

Osteoporosis medication after fracture in older adults: an administrative data analysis

Risk factors for imminent fractures: a substudy of the FRISBEE cohort

Fracture rates in patients discontinuing alendronate treatment in real life: a population-based cohort study

Hospital admissions of patients with osteogenesis imperfecta in the English NHS

Multiple bilateral hip fractures in a patient with dyskeratosis congenita caused by a novel mutation in the PARN gene